Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Sara Mheid; Stefan Allen; Sylvia S.W. Ng; William A. Hall; Nina N. Sanford; Todd A. Aguilera; Ahmed M. Elamir; Rana Bahij; Martijn P.W. Intven; Ganesh Radhakrishna; Issa Mohamad; Jeremy De Leon; Hendrick Tan; Shirley Lewis; Cihan Gani; Teo Stanecu; Veronica Dell’Acqua; Ali Hosni

doi:10.3390/curroncol30100667

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Sara Mheid, Stefan Allen, Sylvia S.W. Ng, William A. Hall, Nina N. Sanford, Todd A. Aguilera, Ahmed M. Elamir, Rana Bahij, Martijn P.W. Intven, Ganesh Radhakrishna, Issa Mohamad, Jeremy De Leon, Hendrick Tan, Shirley Lewis, Cihan Gani, Teo Stanecu, Veronica Dell’Acqua, Ali Hosni

Research output: Contribution to journal › Review article › peer-review

Abstract

The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.

Original language	English (US)
Pages (from-to)	9230-9243
Number of pages	14
Journal	Current Oncology
Volume	30
Issue number	10
DOIs	https://doi.org/10.3390/curroncol30100667
State	Published - Oct 2023
Externally published	Yes

Keywords

SBRT
liver
oligometastases

ASJC Scopus subject areas

Oncology

Access to Document

10.3390/curroncol30100667

Cite this

Mheid, S., Allen, S., Ng, S. S. W., Hall, W. A., Sanford, N. N., Aguilera, T. A., Elamir, A. M., Bahij, R., Intven, M. P. W., Radhakrishna, G., Mohamad, I., De Leon, J., Tan, H., Lewis, S., Gani, C., Stanecu, T., Dell’Acqua, V., & Hosni, A. (2023). Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century. Current Oncology, 30(10), 9230-9243. https://doi.org/10.3390/curroncol30100667

Mheid, S, Allen, S, Ng, SSW, Hall, WA, Sanford, NN , Aguilera, TA, Elamir, AM, Bahij, R, Intven, MPW, Radhakrishna, G, Mohamad, I, De Leon, J, Tan, H, Lewis, S, Gani, C, Stanecu, T, Dell’Acqua, V & Hosni, A 2023, 'Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century', Current Oncology, vol. 30, no. 10, pp. 9230-9243. https://doi.org/10.3390/curroncol30100667

@article{107858fbc6e34db884601a9cc66da1ba,

title = "Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century",

abstract = "The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.",

keywords = "SBRT, liver, oligometastases",

author = "Sara Mheid and Stefan Allen and Ng, {Sylvia S.W.} and Hall, {William A.} and Sanford, {Nina N.} and Aguilera, {Todd A.} and Elamir, {Ahmed M.} and Rana Bahij and Intven, {Martijn P.W.} and Ganesh Radhakrishna and Issa Mohamad and {De Leon}, Jeremy and Hendrick Tan and Shirley Lewis and Cihan Gani and Teo Stanecu and Veronica Dell{\textquoteright}Acqua and Ali Hosni",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = oct,

doi = "10.3390/curroncol30100667",

language = "English (US)",

volume = "30",

pages = "9230--9243",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multimed Inc.",

number = "10",

}

TY - JOUR

T1 - Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases

T2 - Lessons from a Quarter Century

AU - Mheid, Sara

AU - Allen, Stefan

AU - Ng, Sylvia S.W.

AU - Hall, William A.

AU - Sanford, Nina N.

AU - Aguilera, Todd A.

AU - Elamir, Ahmed M.

AU - Bahij, Rana

AU - Intven, Martijn P.W.

AU - Radhakrishna, Ganesh

AU - Mohamad, Issa

AU - De Leon, Jeremy

AU - Tan, Hendrick

AU - Lewis, Shirley

AU - Gani, Cihan

AU - Stanecu, Teo

AU - Dell’Acqua, Veronica

AU - Hosni, Ali

PY - 2023/10

Y1 - 2023/10

N2 - The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.

AB - The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.

KW - SBRT

KW - liver

KW - oligometastases

UR - http://www.scopus.com/inward/record.url?scp=85175273499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85175273499&partnerID=8YFLogxK

U2 - 10.3390/curroncol30100667

DO - 10.3390/curroncol30100667

M3 - Review article

C2 - 37887567

AN - SCOPUS:85175273499

SN - 1198-0052

VL - 30

SP - 9230

EP - 9243

JO - Current Oncology

JF - Current Oncology

IS - 10

ER -

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this